Advancing Global Health
Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and financial support to the most vulnerable communities around the world.
By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.
Helping Eliminate Chronic Hepatitis C Worldwide
The WHO has set the goal of eliminating viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and end the disease.
Gilead and the WHO Tackle VL in Southeast Asia
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 50,000 to 90,000 new cases worldwide each year, out of which only an estimated 25% to 45% are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide treatments free of charge to all people diagnosed with the disease.
